PTO/SB/08A (08-00)

e type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complete if Known					
Application Number	10/684,229				
Filing Date	October 10, 2003				
First Named Inventor	Lin Zhi, et al				
Group Art Unit	To Be Assigned				
Examiner Name	To Be Assigned				
Attorney Docket Number	45026.00128				

	Pages, Columns, Lines,					
Examiner Initials*	Cite No.1	U.S. Patent I Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
CA	AA	5,693,646		Jones, et al	12/02/1997	
CA	AB	5,693,647		Jones, et al	12/02/1997	
CA	AC	5,696,127		Jones, et al	12/09/1997	
				- 194		
	-					
	ļ			<u> </u>		
	L					

FOREIGN PATENT DOCUMENTS									
Examiner	Cite		Foreign Patent Doc		Name of Patentee or	Date of Publication of	Pages, Columns, Lines,	\neg	
Initials	No.1	Office ³	Number⁴	Kind Code ¹ (if known)	Applicant of Cited Document	. Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T	
CA	AD	WO	99/41256	Al	Wang, et al	08/19/1999	-	Т	
CA	AE	WO	99/41257	Al	Coughlin, et al	04/30/2002		\top	
		1							

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No."	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
CA	AF	Berger, T. S., et al., Interaction of Glucocorticoid Analogues with the Human Glucocorticoid Receptor. J. Steroid Biochem. Mol. Bio. 1992, 41, 733-738				
CA	AG	Pathirana, C., et al., Nonsteroidal Human Progesterone Receptor Modulators from the Marine Alga Cymopolia Babata. Mol. Pharm. 1995, 47, 630-635				

Examiner SAN/80520 Signature	AULAKH	Date Considered	12-28-04

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

APR 26

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Complete if Known

Application Number 10/684,229

Filing Date October 10, 2003

First Named Inventor Lin Zhi, et al.

Group Art Unit To Be Assigned

Examiner Name To Be Assigned

Attorney Docket Number 45026.00128.UTL

(use as many sheets as necessary)
Sheet 1 of 2

	U.S. PATENT DOCUMENTS								
Eveninor	Cite	U.S. Pate	nt Document	Name of Patentee or	Date of Publication of	Pages, Columns, Lines.			
Examiner Cite Initials* No.1				Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Retovant Passages or Retevant Figures Appear			
-									
						······································			

FOREIGN PATENT DOCUMENTS								
Examiner	Cite		Foreign Patent Doc	ument	Name of Patentee or	Date of Publication of	Pages, Columns, Lines,	
Initials	No.	Office3	Number ⁴	Kind Code ⁵ (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	7*
CA	AA	WO	02/02565		Coghlan et al.	01-10-2002		
			,					-

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
CA	AB	International Search Report for Corresponding Application PCT/US03/24419 filed August 4, 2003 (dated January 29, 2004).					
CA	AC	TEGLEY, Christopher et al., "5-Benzylidene 1,2-Dihydrochromeno[3,4-f]quinolines, A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists", Journal of Medicinal Chemistry, American Chemical Society. Washington, US, vol. 41, no. 3, 1998, pages 4354-4359.					
CA	AD	ZHI, Lin et al., "5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists", <i>Journal of Medicinal Chemistry</i> , American Chemical Society. Washington, US, vol. 41, no. 3, 1998, pages 291-302.					
CA	AE	ZHI, L. et al., "5-Alkyl 1,2-Dihydrochomeno[3-4f]quinolines: A Novel Class of Nonsteroidal Progesterone Receptor Modulators", <i>Bioorganic & Medicinal Chemistry Letters</i> , Oxford GB, vol. 8, no. 23, 1 December 1998, pages 3365-3370.					

Examiner Signature	SAN/88135.1	AULAKH	Date Considered	12-28-04

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00) se type a plus sign (+) inside this box -> + Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	Substitute for form 14-	49A/PTO	,	Complete if Known		
IN	IFORMATIO	או חופרו ו	ACLIÈE	Application Number	10/684,229	
				Filing Date	October 10, 2003	
S	TATEMENT	BY APPL	LICAN I	First Named Inventor	Lin Zhi et al.	
				Group Art Unit	To Be Assigned	
	(use as many sheets as necessary)			Examiner Name	To Be Assigned	
Sheet	2	of	2	Attorney Docket Number	45026.00128.UTL	

	NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.'	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²					
CA	AF	ZHI, Lin et al., "Novel Class of Non-Steroidal Progesterone Receptor Antagonist", Expert Opinion on Therapeutic Patents, Ashley Publications, GB, vol. 9, no. 6, 1999, pages 695-700.						
		·						

Examiner	SAN/88135.1 A	Date	10 20.3/1
Signature	HDLHG1	Considered	12-2009

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.